CEREMARK PHARMA

CereMark Pharma is a clinical-stage radiopharmaceutical company focused on developing new and superior imaging tools that enable precision in predicting the development of Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE) in those individuals presenting with the uncertainty of mild cognitive impairment... As we head into Phase 3 clinical trials for F-18 Flornaptitril, CereMark Pharma is proud to have partnered with technological leaders, patient advocacy groups, industry associations, academic centers, hospitals and healthcare providers that share our passion for improving the management and care of patients with some of life's most debilitating neurological diseases. But we're not done yet!... CereMark Pharma™ is committed to developing innovative new PET imaging radiopharmaceuticals that bring highly precise visibility into the progression of neurodegenerative diseases in living brains.

Primary location: Wheeling United States